Paper25482425
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Büller HR and 9 others. N Engl J Med, 2015. Cited by 532 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Factor XI antisense oligonucleotide for prevention of venous thrombosis. Papers, record 25482425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25482425
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticoagulants | Major topic |
| Arthroplasty, Replacement, Knee | Major topic |
| Factor XI | Major topic |
| Oligonucleotides | Major topic |
| Oligonucleotides, Antisense | Major topic |
| Postoperative Complications | Major topic |
| Venous Thrombosis | Major topic |
| Adult | |
| Aged | |
| Blood Coagulation | |
| Clinical Protocols | |
| Enoxaparin | |
| Female | |
| Hemorrhage | |
| Humans | |
| Length of Stay | |
| Male | |
| Middle Aged | |
| Partial Thromboplastin Time |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HL058837 | NHLBI NIH HHS | United States | R01HL058837 | PubMed and NIH | NIH RePORTER |
| R01 HL081326 | NHLBI NIH HHS | United States | R01HL081326 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01713361 | Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 25,482,334 | Making (anti)sense of factor XI in thrombosis. | https://conductscience.org/library/papers/25482334 | PubMed |
| Comment in | 25,533,800 | Anticoagulation therapy: Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism. | https://conductscience.org/library/papers/25533800 | PubMed |
| Comment in | 25,901,434 | Factor XI antisense oligonucleotide for venous thrombosis. | https://conductscience.org/library/papers/25901434 | PubMed |
| Comment in | 25,901,435 | Factor XI antisense oligonucleotide for venous thrombosis. | https://conductscience.org/library/papers/25901435 | PubMed |
| Comment in | 25,901,436 | Factor XI antisense oligonucleotide for venous thrombosis. | https://conductscience.org/library/papers/25901436 | PubMed |
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22,315,265 | Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | Chest | 2012 | https://conductscience.org/library/papers/22315265 | PubMed |
| 2 | 20,807,891 | Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. | Blood | 2010 | https://conductscience.org/library/papers/20807891 | PubMed |
| 3 | 23,615,791 | Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. | Thromb Haemost | 2013 | https://conductscience.org/library/papers/23615791 | PubMed |
| 4 | 23,559,626 | Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. | Arterioscler Thromb Vasc Biol | 2013 | https://conductscience.org/library/papers/23559626 | PubMed |
| 5 | 22,246,038 | Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. | Blood | 2012 | https://conductscience.org/library/papers/22246038 | PubMed |
| 6 | 20,005,807 | Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. | Cell | 2009 | https://conductscience.org/library/papers/20005807 | PubMed |
| 7 | 19,617,576 | Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. | Blood | 2009 | https://conductscience.org/library/papers/19617576 | PubMed |
| 8 | 18,945,968 | Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. | Blood | 2009 | https://conductscience.org/library/papers/18945968 | PubMed |
| 9 | 18,288,180 | Triggers, targets and treatments for thrombosis. | Nature | 2008 | https://conductscience.org/library/papers/18288180 | PubMed |
| 10 | 20,723,033 | A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. | J Thromb Haemost | 2010 | https://conductscience.org/library/papers/20723033 | PubMed |
| 11 | 21,057,700 | Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. | Thromb Haemost | 2011 | https://conductscience.org/library/papers/21057700 | PubMed |
| 12 | 24,366,358 | Thrombosis: tangled up in NETs. | Blood | 2014 | https://conductscience.org/library/papers/24366358 | PubMed |
| 13 | 10,706,899 | High levels of coagulation factor XI as a risk factor for venous thrombosis. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10706899 | PubMed |
| 14 | 1,652,157 | Factor XI activation in a revised model of blood coagulation. | Science | 1991 | https://conductscience.org/library/papers/1652157 | PubMed |
| 15 | 16,961,605 | Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. | J Thromb Haemost | 2006 | https://conductscience.org/library/papers/16961605 | PubMed |
| 16 | 17,405,864 | Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17405864 | PubMed |
| 17 | 17,855,670 | Idraparinux versus standard therapy for venous thromboembolic disease. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17855670 | PubMed |
Cited by281
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 532 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,936,593 | Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936593 | PubMed |
| 42,936,574 | Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936574 | PubMed |
| 42,936,046 | Perspectives: what we are learning from factor XI/factor XIa inhibitor trials. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936046 | PubMed |
| 42,898,680 | Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898680 | PubMed |
| 42,881,892 | Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881892 | PubMed |
| 42,628,751 | Structural insights into the exosite-mediated activation of factor IX by factor XIa using cryogenic electron microscopy. | J Thromb Haemost | 2026 | https://conductscience.org/library/papers/42628751 | PubMed |
| 42,318,380 | Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model. | Blood Vessel Thromb Hemost | 2026 | https://conductscience.org/library/papers/42318380 | PubMed |
| 42,275,249 | Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat). | Blood | 2026 | https://conductscience.org/library/papers/42275249 | PubMed |
| 42,260,521 | Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations. | Thromb J | 2026 | https://conductscience.org/library/papers/42260521 | PubMed |
| 42,026,656 | Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies. | Cardiooncology | 2026 | https://conductscience.org/library/papers/42026656 | PubMed |
| 42,022,599 | Asundexian Versus Apixaban in Patients With Atrial Fibrillation. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42022599 | PubMed |
| 41,977,337 | Pharmacological Management of Thrombosis: Current State and Future Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977337 | PubMed |
| 41,899,496 | From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899496 | PubMed |
| 41,879,908 | Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials. | Adv Ther | 2026 | https://conductscience.org/library/papers/41879908 | PubMed |
| 41,802,667 | Targeting factor XI for venous thromboembolism prevention: a tale of 2 antibodies. | J Thromb Haemost | 2026 | https://conductscience.org/library/papers/41802667 | PubMed |
| 41,677,103 | Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation. | Clin Cardiol | 2026 | https://conductscience.org/library/papers/41677103 | PubMed |
| 41,581,095 | Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions. | Am J Cardiovasc Drugs | 2026 | https://conductscience.org/library/papers/41581095 | PubMed |
| 41,512,172 | RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). | Blood Adv | 2026 | https://conductscience.org/library/papers/41512172 | PubMed |
| 41,304,947 | Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304947 | PubMed |
| 41,222,225 | Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events. | CPT Pharmacometrics Syst Pharmacol | 2025 | https://conductscience.org/library/papers/41222225 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| F10 | 2,159 | PubTator's text mining | https://conductscience.org/library/genes/2159 | NCBI Gene |
| F11 | 2,160 | PubTator's text mining | https://conductscience.org/library/genes/2160 | NCBI Gene |
| F12 | 2,161 | PubTator's text mining | https://conductscience.org/library/genes/2161 | NCBI Gene |
| F2 | 2,147 | PubTator's text mining | https://conductscience.org/library/genes/2147 | NCBI Gene |
| RNASEH1 | 246,243 | PubTator's text mining | https://conductscience.org/library/genes/246243 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25482425
GET https://conductscience.org/api/papers/v1/25482425/cited_by?page=2